Vaisala Group
29.8.2025 17:30:00 CEST | Globenewswire | Press release
Vaisala Corporation: Share Repurchase 29.8.2025
Vaisala Corporation: Share Repurchase 29.8.2025
| VAISALA CORPORATION | STOCK EXCHANGE RELEASE 29.8.2025 | |
| Vaisala Corporation: Share Repurchase 29.8.2025 | ||
| In the Helsinki Stock Exchange | ||
| Trade date | 29.8.2025 | |
| Bourse trade | Buy | |
| Share | VAIAS | |
| Amount | 3 000 | Shares |
| Average price/ share | 46,2000 | EUR |
| Total cost | 138 600,00 | EUR |
| Vaisala Corporation now holds a total of 157 300 shares | ||
| including the shares repurchased on 29.8.2025 | ||
| The share buybacks are executed in compliance with Regulation | ||
| No. 596/2014 of the European Parliament and Council (MAR) Article 5 | ||
| and the Commission Delegated Regulation (EU) 2016/1052. | ||
| On behalf of Vaisala Corporation | ||
| Nordea Bank Oyj | ||
| Sami Huttunen | Ilari Isomäki | |
More information:
Niina Ala-Luopa
+358 400 728 957, ir@vaisala.com
Distribution:
Nasdaq Helsinki
Key media
vaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. www.vaisala.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom